UK
IE
Maisie Borrows Ahmad
I am Strategic Growth Lead in the Health Analytics team, with more than 10 years’ experience working across the life sciences and healthcare ecosystem.
I previously worked in the pharmaceutical industry, developing expertise in market access, government affairs and strategy. During this time, I co-developed projects looking at tackling health inequalities in patient outcomes and I am looking forward to continuing to support this mission at LCP. I have a thorough understanding of healthcare policy, having previously worked in the public-service specialist think tank Reform. I have consulted for large clients in healthcare, including the UK's National Health Service (NHS), in my previous role as a management consultant at PwC.
These experiences mean I am well-versed in understanding the complex challenges companies face navigating the health system and ensuring their innovations have the most impact for patients. In my role as Strategic Growth Lead, I look forward to supporting clients to address their key issues, as well as spotting opportunities to better use health data to inform insight-driven decisions.
Beyond my day-to-day role, I am also a member of the LCP Foundation Committee.
I have a BSc in Psychology from University College London and an MBA from IMD Business School, Switzerland. I am a certified practitioner in the LUMA design thinking methodology, and I have a sound understanding of the ABPI Code of Practice.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
